Page 160 - 2019_04-Haematologica-web

C. Recasens-Zorzo et al.
51. Stamatopoulos B, Meuleman N, De BC, et
al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse- like cell-based microenvironment: pre-clin- ical evidence for its association with chron- ic lymphocytic leukemia treatments. Haematologica. 2012;97(4):608-615.
52. Pettersson S, Perez-Nueno VI, Ros-Blanco L, et al. Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors. ChemMedChem. 2008;3(10): 1549-1557.
53. Kashyap MK, Amaya-Chanaga CI, Kumar D, et al. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017;10(1):112.
54. Valera A, López-Guillermo A, Cardesa- Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunoche- motherapy. Haematologica. 2013;98(10):
1554-1562.
55. Hatano K, Yamaguchi S, Nimura K, et al.
Residual prostate cancer cells after docetax- el therapy increase the tumorigenic poten- tial via constitutive signaling of CXCR4, ERK1/2 and c-Myc. Mol Cancer Res. 2013;11(9):1088-1100.
56. Filippakopoulos P, Knapp S. Targeting bro- modomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13(5):337-356.
57. Diaz T, Rodriguez V, Lozano E, et al. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexametha- sone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica. 2017;102(10):1776-1784.
58. Boi M, Gaudio E, Bonetti P, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015;21(7):1628- 1638.
59.
60.
61.
62.
Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A. 2014;111(31):11365-11370. Esteve-Arenys A, Valero JG, Chamorro- Jorganes A, et al. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene. 2018;37(14):1830-1844. Chapuy B, McKeown MR, Lin CY, et al. Discovery and characterization of super- enhancer-associated dependencies in dif- fuse large B cell lymphoma. Cancer Cell. 2013;24(6):777-790.
Moros A, Bustany S, Cahu J, et al. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lym- phoma involves the destabilization of cyclin D1/p27KIP1 complexes. Clin Cancer Res. 2014;20(2):393-403.
788
haematologica | 2019; 104(4)